SecBot SecBot
6-K ·Filed Jul 27, 2026

ARGX

ARGENX SE
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001104659-26-086760
Actionable Insight ▲ Bullish

This is a strategically sound, cash-funded bolt-on acquisition that expands argenx's immunology pipeline into a new mechanism (anti-CD122) with validated clinical data. Monitor the investor call at 8:00 AM ET for details on FB102's development timeline and potential peak revenue estimates. The stock should re-rate upward as the market prices in the pipeline expansion without dilution risk.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ARGX drug pipeline →

empasiprubart

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
Several years away, if successful. Phase 3 MMN trial won't complete final data collection until December 2029. A potential BLA submission would follow positive Phase 3 data, likely no earlier than 2027-2028.
Next catalyst
None dated

What to watchWatch for Phase 3 topline MMN data (estimated primary completion Sep 2026). Positive data could add a new pipeline pillar, but empasiprubart is not the primary value driver at argenx, Vyvgart's commercial trajectory and the myositis readout for efgartigimod are larger stock-moving events. A Phase 2 dermatomyositis readout is also expected by November 2026.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$888.82
T+0 close · Jul 27, 2026 · via day close
Latest settled
−7.11%
T+60 · $825.61
Vs SPY
−10.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $888.82entry
  2. T+1 · 4mo ago −1.87%α −2.11% · $872.23
  3. T+5 · 4mo ago −3.94%α −5.01% · $853.82
  4. T+20 · 3mo ago +13.76%α +10.46% · $1,011.11
  5. T+60 · 28d ago −7.11%α −10.82% · $825.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a total equity value of approximately $2.2 billion, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline. The acquisition, funded entirely from cash on hand and expected to close in Q3 2026, provides argenx with a pipeline-in-a-product opportunity with clinical proof-of-concept in vitiligo and celiac disease, broadening its portfolio beyond FcRn biology into T-cell and NK-cell mediated autoimmune diseases. The deal represents a strategic bolt-on that strengthens argenx's long-term growth narrative without diluting shareholders or adding debt.

Key Facts

  • argenx to acquire Forte Biosciences for $77 per share in cash, total equity value of approximately $2.2 billion.
  • The acquisition adds FB102, a first-in-class anti-CD122 antibody with Phase 1b proof-of-concept in vitiligo and celiac disease.
  • Transaction is not subject to a financing condition and will be funded entirely from cash on hand.
  • Acquisition expected to close in Q3 2026, subject to customary conditions including HSR clearance.
  • FB102 has potential pipeline-in-a-product opportunity across multiple autoimmune diseases including alopecia areata.
  • argenx CEO Karen Massey stated the acquisition aligns with the company's Vision 2030 strategy.

Financial Impact

All-cash acquisition of $2.2 billion total equity value, funded from cash on hand with no financing condition.

cashpipeline valueR&D expenditure

Risk Factors

  • Integration risk of Forte Biosciences' operations and clinical programs.
  • Regulatory risk: HSR clearance and other customary closing conditions could delay or block the transaction.
  • Clinical risk: FB102's Phase 2 data in celiac disease (expected H2 2026) and future trials may not replicate Phase 1b results.
  • Competitive risk in the autoimmune space, particularly for T-cell mediated therapies.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (ARGX), Batch item 10001104659-26-086760
Document: tm2621326d1_6k.htm0001104659-26-086760
Document: 0001104659-26-086760-index-headers.html0001104659-26-086760
Document: 0001104659-26-086760-index.html0001104659-26-086760
Document: 0001104659-26-086760.txt0001104659-26-086760
6-K Filing (ARGX), Batch item 60001104659-26-086760
Document: tm2621326d1_6k.htm0001104659-26-086760
Document: 0001104659-26-086760-index-headers.html0001104659-26-086760
Document: 0001104659-26-086760-index.html0001104659-26-086760
Document: 0001104659-26-086760.txt0001104659-26-086760

Track record

23 reports on ARGX

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  2. Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
  5. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
  6. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
  7. Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
  8. Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
  9. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
  10. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026